Hims & Hers Stumbles as GLP-1 Compounding Ends. Lilly Presses the Advantage.
Eli Lilly releases cheaper vials of the weight-loss drug for self-paying patients and cuts the price of two existing doses.
Hims & Hers shares plunge as looming curbs on drug compounding cloud forecast
Hims & Hers Health shares were headed for their biggest single-day plunge as Wall Street analysts questioned the telehealth ...
FiercePharma14h
Compounders sue FDA again over declaring end of shortage for Novo's semaglutide
Compounding pharmacies aren’t surrendering their ability to create cheaper knockoff versions of Eli Lilly and Novo Nordisk’s ...
Hims & Hers warns it may stop selling compounded weight-loss drugs
Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...
Generic Wegovy, Ozempic compounds may become harder to get as FDA removes drug from shortage list
Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...
BioSpace15h
Compounders Sue FDA for Declaring Ozempic, Wegovy Shortage Over
The Outsourcing Facilities Association, a trade group representing compounders, filed a similar lawsuit in October last year ...
Costs could rise for people using copycats of Ozempic, Wegovy
People who have depended on off-brand versions of Wegovy and Ozempic will likely have to pay more now that a nationwide ...
Acre Raises $4M at $90M Valuation, Unlocking Bitcoin-Native Compounding for BTC Holders
With its Bitcoin-in, Bitcoin-out model, Acre simplifies compounding for BTC holders while empowering decentralized networks ...
Becker's Hospital Review1d
FDA sets deadline to end sales of Ozempic, Wegovy copycats
Semaglutide — the key ingredient in Ozempic and Wegovy — had been in shortage since 2022. Now that supply has stabilized, state-licensed compounding pharmacies and physicians must stop selling ...